Chorea: Clinical Trials

5 trials for Chorea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Terminated 5

Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
SAGE-718 - Huntington's Disease
Phase 3TerminatedSupernus Pharmaceuticals, Inc.1532022-12-142025-12-17
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Valbenazine - Chorea, Huntington
Phase 3TerminatedNeurocrine Biosciences1542020-09-182026-11-03
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
Dimebon (latrepirdine) - Huntington Disease
Phase 3TerminatedMedivation, Inc.3622010-02-012016-10-12
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Creatine Monohydrate, Placebo - Huntington's Disease
Phase 3TerminatedMassachusetts General Hospital5532009-09-012016-03-11
Coenzyme Q10 in Huntington's Disease (HD)
coenzyme Q10, placebo - Huntington's Disease
Phase 3TerminatedMassachusetts General Hospital6092008-03-012016-03-30

Narrower conditions

Huntington Disease (5)  ·  Mitochondrial Diseases (1)

Broader conditions

Basal Ganglia Diseases (5)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Cognition Disorders (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Dementia (5)  ·  Dyskinesias (5)  ·  Genetic Diseases, Inborn (5)  ·  Heredodegenerative Disorders, Nervous System (5)  ·  Mental Disorders (5)  ·  Movement Disorders (5)  ·  Nervous System Diseases (5)  ·  Neurocognitive Disorders (5)  ·  Neurodegenerative Diseases (5)

Interventions

Creatine (1)  ·  Glucose (1)  ·  coenzyme Q10 (1)  ·  latrepirdine (1)  ·  valbenazine (1)

Sponsors

Massachusetts General Hospital (2)  ·  Medivation, Inc. (1)  ·  Neurocrine Biosciences (1)  ·  Supernus Pharmaceuticals, Inc. (1)

Countries

Canada (4)  ·  United States (4)  ·  Australia (3)  ·  New Zealand (1)  ·  United Kingdom (1)

Top investigators

Diana Rosas, MD, MS (1)  ·  Giovanni Schifitto, MD (1)  ·  Karl Kieburtz, MD MPH (1)  ·  Merit Cudkowicz, MD MSc (1)  ·  Michael McDermott, PhD (1)  ·  Steven M Hersch, MD, PhD (1)

Results publications

PMID 35747889, PMID 27913695, PMID 28701493, PMID 30103342, PMID 30850442

NIH funding

R01NS052619 (1), U01AT000613 (1), U01NS052592 (1)